Chang H. Park

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Andrew J. Souers, Joel D. Leverson, Erwin R. Boghaert et al. · Nature Medicine · 2013 · 3K citations

Medicine, Oncology, Pharmacology +10

Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer

Emily J. Faivre, Keith F. McDaniel, Daniel H. Albert et al. · Nature · 2020 · 404 citations

Life Sciences, Molecular Biology, Oncology +10

Structure of Human Des(1-45) Factor Xa at 2·2 Å Resolution

K. Padmanabhan, K. Padmanabhan, A. Tulinsky et al. · Journal of Molecular Biology · 1993 · 392 citations

Life Sciences, Biology, Molecular Biology +13

Discovery of a Potent and Selective BCL-X _L Inhibitor with <i>in Vivo</i> Activity

Zhi‐Fu Tao, Lisa Hasvold, Le Wang et al. · ACS Medicinal Chemistry Letters · 2014 · 331 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10

Potential mechanisms of resistance to venetoclax and strategies to circumvent it

Stephen K. Tahir, Morey L. Smith, Paul Hessler et al. · BMC Cancer · 2017 · 187 citations · Full text

Medicine, Oncology, Pharmacology +17